Literature DB >> 11254650

Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.

A Qamar1, S Aboudola, M Warny, P Michetti, C Pothoulakis, J T LaMont, C P Kelly.   

Abstract

Saccharomyces boulardii is a nonpathogenic yeast that protects against antibiotic-associated diarrhea and recurrent Clostridium difficile colitis. The administration of C. difficile toxoid A by gavage to S. boulardii-fed BALB/c mice caused a 1.8-fold increase in total small intestinal immunoglobulin A levels (P = 0.003) and a 4.4-fold increase in specific intestinal anti-toxin A levels (P < 0.001). Enhancing host intestinal immune responses may be an important mechanism for S. boulardii-mediated protection against diarrheal illnesses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254650      PMCID: PMC98222          DOI: 10.1128/IAI.69.4.2762-2765.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii.

Authors:  J Hassett; S Meyers; L McFarland; M E Mulligan
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

Review 2.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

3.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Authors:  M Warny; J P Vaerman; V Avesani; M Delmée
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

4.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

5.  Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants.

Authors:  J P Buts; G Corthier; M Delmee
Journal:  J Pediatr Gastroenterol Nutr       Date:  1993-05       Impact factor: 2.839

6.  Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

Authors:  C P Kelly; C Pothoulakis; J Orellana; J T LaMont
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

7.  Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.

Authors:  M B Kimmey; G W Elmer; C M Surawicz; L V McFarland
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199

8.  [Influence of Saccharomyces boulardii on jejunal secretion in rats induced by cholera toxin].

Authors:  N Vidon; B Huchet; J C Rambaud
Journal:  Gastroenterol Clin Biol       Date:  1986-01

9.  Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen.

Authors:  C O Elson; W Ealding
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

10.  The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins.

Authors:  I Just; M Wilm; J Selzer; G Rex; C von Eichel-Streiber; M Mann; K Aktories
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

View more
  51 in total

1.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

Review 2.  The human mycobiome.

Authors:  Patrick C Seed
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 3.  Bugs or drugs: are probiotics safe for use in the critically ill?

Authors:  Lindsay M Urben; Jennifer Wiedmar; Erica Boettcher; Rodrigo Cavallazzi; Robert G Martindale; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2014

Review 4.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 5.  Effects of Saccharomyces boulardii on intestinal mucosa.

Authors:  Jean-Paul Buts; Nadine De Keyser
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

6.  Treatment of Recurrent Clostridium difficile Diarrhea.

Authors:  Elizabeth S Huebner; Christina M Surawicz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

7.  A Mutation in PGM2 Causing Inefficient Galactose Metabolism in the Probiotic Yeast Saccharomyces boulardii.

Authors:  Jing-Jing Liu; Guo-Chang Zhang; In Iok Kong; Eun Ju Yun; Jia-Qi Zheng; Dae-Hyuk Kweon; Yong-Su Jin
Journal:  Appl Environ Microbiol       Date:  2018-05-01       Impact factor: 4.792

8.  Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study.

Authors:  Hyun Joo Song; Jin-Yong Kim; Sung-Ae Jung; Seong-Eun Kim; Hye-Sook Park; Yoolwon Jeong; Sung Pil Hong; Jae Hee Cheon; Won Ho Kim; Hyo-Jong Kim; Byong Duk Ye; Suk-Kyun Yang; Sang-Woo Kim; Sung-Jae Shin; Hyun-Soo Kim; Jae-Kyu Sung; Eun Young Kim
Journal:  J Korean Med Sci       Date:  2010-11-24       Impact factor: 2.153

Review 9.  Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.

Authors:  C Pothoulakis
Journal:  Aliment Pharmacol Ther       Date:  2008-07-23       Impact factor: 8.171

10.  Saccharomyces boulardii prevents oral-poliovirus vaccine-induced IgA nephropathy in mice.

Authors:  Alper Soylu; Sema Berktaş; Sülen Sarioğlu; Güven Erbil; Osman Yilmaz; Belde K Demir; Yahya Tufan; Didem Yeşilirmak; Mehmet Türkmen; Salih Kavukçu
Journal:  Pediatr Nephrol       Date:  2008-04-30       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.